Skip to main content
main-content

08.04.2018 | Original Article

Comparison of anticancer effects of everolimus-gemcitabine combination with gemcitabine on pancreatic cancer using Rgs16 biomarker evaluation

Zeitschrift:
Comparative Clinical Pathology
Autoren:
Yalda Zolghadri, Mehdi Fazeli

Abstract

Pancreatic cancer is a highly metastatic cancer with an exceptionally poor prognosis. Despite development of different drugs and combined therapies, advances in survival rate still remain low and slow, mainly due to the invasiveness and late diagnosis. Therefore, it is crucial to find an effective treatment for invasiveness. The first-line therapy for pancreatic cancer is gemcitabine. Everolimus is another drug with benefits in gemcitabine-refractory metastasis. Rgs16 has a role in inhibition of pancreatic cancer migration and invasion. Accordingly, we aimed to investigate to which extent a combination of everolimus and gemcitabine is effective in killing highly metastatic pancreatic cancer cells and alter the expression of Rgs16 indicating its usefulness in invasiveness. Gemcitabine, everolimus, and a combination of both drugs were added to cultured Panc-1 cells. The cell killing effects of the drugs were tested through alamar blue assay and cell count. The expression of Rgs16 gene and protein was measured by qPCR and Western blotting. This study showed that a combination of everolimus and gemcitabine is more potent than everolimus, which is more effective than gemcitabine, in killing pancreatic cancer cells. However, Rgs16 as a marker of invasion was very low in Panc-1 cells and the drugs were not effective in altering Rgs16 gene expression or protein level. Although this may suggest that Panc-1 is a very invasive cell line and these drugs are not effective in highly metastatic cases, the cell line might be resistant to Rgs16 expression due to its specific mutations.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Jetzt abonnieren und bis 25. Juni einen 50 € Amazon-Gutschein sichern.

Literatur
Über diesen Artikel

Neu im Fachgebiet Pathologie

02.05.2018 | Übersichten | Ausgabe 3/2018

Altersschätzung auf Basis der DNA-Methylierung

Reif für den Einsatz zur „Feststellung“ des chronologischen Lebensalters von jungen Migranten ohne valide Identitätsdokumente?

27.04.2018 | Schwerpunkt: Digitale Medizin 2018 | Ausgabe 3/2018

Umsetzung des Leitfadens „Digitale Pathologie in der Diagnostik“

Unterstützende Systeme und ihre Funktionalität

26.04.2018 | CME | Ausgabe 3/2018

Die neue S3-Leitlinie „Prävention des Zervixkarzinoms“

Was ist wichtig für die Pathologie?

24.04.2018 | Schwerpunkt: Digitale Medizin 2018 | Ausgabe 3/2018

Digitale Pathologie

Die Zeit ist reif!